Navigation Links
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Date:9/4/2007

t many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for the treatment of platinum-resistant or -refractory SCLC in nearly a decade.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research an
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... CryoLife, Inc. (NYSE: CRY), a leading medical ... vascular surgery, announced today that its Board of Directors ... quarter 2014 of $0.03 per share of common stock ... will be paid on September 19, 2014 to all ... The ex-dividend date for the quarterly dividend is September ...
(Date:7/30/2014)... 30, 2014 PuraMed BioScience ® , ... over-the-counter (OTC) medicinal and healthcare products, announced today ... name along with the name,s red and yellow ... trademarked name MigraPure ®  going forward. The ... homeopathic, natural migraine pain reliever will be reintroduced ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
Breaking Medicine Technology:CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3
(Date:7/31/2014)... Parsippany, NJ (PRWEB) July 31, 2014 A ... millions of people survive cancer and resume normal lives. This ... American Cancer Society, will affect one in seven American men ... are, has a five-year survival rate of nearly 100% and ... serious illness but most men diagnosed with the disease do ...
(Date:7/31/2014)... its latest blog post, Best Drug Rehabilitation , which ... during a stay in rehab can make a big difference ... at 11 drug addiction facts that children aren’t taught in ... some kids learn a little about the dangers of alcohol ... woefully inadequate,” commented Best Drug Rehabilitation’s Per Wickstrom . ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Continuing ... the upcoming inaugural Clinical Issues in Primary Care ... October 13-17, 2014 at the Wailea Beach Marriott Resort ... agenda has been developed for today's Primary Care ... critical CME topics," says Barbara Lyons, VP Education. , ...
(Date:7/31/2014)... 31, 2014 Nuanced Media, a leading ... of the Nuanced Medical website . Nuanced Medical, ... needs of the Medical Industry. , The idea behind ... for medical practices to meet continuously changing federal regulations. ... HIPAA Act (Health Insurance Portability and Accountability Act), which ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The ... with the Penn's Abramson Cancer Center, will host a ... together area experts in the field of mesothelioma. September ... The conference is open to the public, and specifically ... and those who have been exposed to asbestos. , ...
Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:New Best Drug Rehabilitation Blog Posts Looks at 11 Drug Addiction Facts they Don’t Teach in School 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 2Health News:Clinical Issues in Primary Care Continuing Medical Education (CME) Conference - October 13-17, 2014 in Maui, Hawaii - Agenda Released 3Health News:Nuanced Media, HIPAA Certified Agency, Launches Medical Web Design Service Website 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3
... study in the Sept.1 issue of the journal ... workplace bullying is associated with increased sleep disturbances. Associations ... indicating that bullying has detrimental effects even when it ... high prevalence of workplace bullying, with 11 percent of ...
... More than 1,000 Reported Incidents, Caregivers Call for Comprehensive Process to ... Aug. 31 Home care workers called for a hand-examination ... the workers, union, saying they had been subjected to lies, coercion, ... members of the Service Employees International Union, United Healthcare Workers - ...
... Insurance company ... flight , ... August 31, 2009 -- Last year, Sally (a patient suffering from end stage liver failure) ... transplant. Her doctors told her she needed to receive the evaluation in order to get ...
... , , SAN FRANCISCO, ... full-service direct marketing agency staffed with seasoned marketing professionals and a ... appointed Robin Raff to the position of Director of Strategy for ... Raff reports directly to ECI CEO and President Bara Oscodar. ...
... , LAKE FOREST, Ill., Aug. 31 ... in generic injectable pharmaceuticals, today announced that the U.S. Food and ... presentations of therapeutic heparin in single- and multiple-dose vials. , ... central venous catheters and for anticoagulant (blood thinning) therapy, and is ...
... , , , SCOTTSDALE, Ariz., Aug. ... failure) was in need of life flight transportation ... needed to receive the evaluation in order to get on the transplant ... due to her condition. Her health insurance company told her they would ...
Cached Medicine News:Health News:Workplace bullying is associated with sleep disturbances 2Health News:Workplace bullying is associated with sleep disturbances 3Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 2Health News:San Francisco Home Care Workers Describe Lies, Coercion, and Fraud in Union Signature Drive 3Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3Health News:ECI Hires Robin Raff as Director of Strategy 2Health News:Hospira Receives FDA Approval for Six New Presentations of Heparin 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 2Health News:In Final Hour Prior to Litigation, Angel MedFlight's Air Ambulance Team Overturns Decision by Major Insurance Company 3
Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
Wright-Giemsa Stain Solutions...
Medicine Products: